Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Results Published demonstrates the ability of ultra-potent monoclonal antibodies to completely neutralize the SARS-CoV-2 virus. These ultra-potent antibodies neutralize the SARS-CoV-2 virus with similar potencies as monoclonal antibodies published in peer-reviewed journals.
Lead Product(s): IDB003
Therapeutic Area: Infections and Infectious Diseases Product Name: IDB003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
For assessment and future licensing and clinical development, certain monoclonal antibodies discovered in Dr. James Crowe's laboratory at the Vanderbilt Vaccine Center will be shared with IDBiologics.
Lead Product(s): Monoclonal antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vanderbilt University Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2020